HeartSciences Announces Publication of Clinical Study Results in the Journal of the American College of Cardiology (JACC)
HeartSciences, a medical device company leading innovation in electrocardiography through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence, announced today the results of a clinical study serially conducted at The Icahn School of Medicine, Mount Sinai Hospital, New York, NY and the West Virginia University (WVU) Heart and Vascular Institute, Morgantown, WV. The results were provided at onlineJACC.org, April 09, 2018 and will be published in the April 17, 2018 issue of Journal of the American College of Cardiology (JACC), a peer-reviewed journal in cardiovascular medicine.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180410005607/en/
HeartSciences’ MyoVista wavECG Device with Informatics (Photo: Business Wire)
The article titled “Prediction of Abnormal Myocardial Relaxation from Signal Processed Surface ECG” presents the results from the investigator-initiated clinical study that focused on evaluating the feasibility of MyoVista ® Wavelet ECG (wavECGTM) as a diagnostic tool for predicting myocardial relaxation abnormalities. Abnormal relaxation is an early feature of many types of heart disease and a key characteristic of left ventricular diastolic dysfunction (LVDD). It is typically detected using echocardiographic imaging. LVDD is a strong predictor of cardiovascular and all-cause mortality.1 Ischemia, hypertension, diabetes, valvular disease and reduced systolic function are all associated with LVDD.1, 2
Results from the feasibility study demonstrate MyoVista patented technology can detect myocardial relaxation abnormalities associated with LVDD. The study results demonstrated 80% sensitivity and 84% specificity with an area under the curve of 91% for the prediction of low (e’), an echocardiographic parameter widely used in determination of LVDD. Prediction of low (e’) also correctly identified 23 out of 28 study subjects (82%) with significant underlying coronary artery disease. Additionally, MyoVista wavECG prediction of relaxation abnormalities also allowed recognition of subjects with more advanced stages of DD and concurrent CAD with significantly more incremental value compared with clinical variables and conventional ECG information. The feasibility study was performed using machine learning analysis often described as artificial intelligence or AI. The study included a limited number of patients as well as other limitations and future studies were recommended to address these limitations.
Conclusions of the trial suggest a potential role for the MyoVista wavECG Device as a screening tool for patients at risk for LVDD that would benefit from echocardiographic evaluations.
Partho Sengupta, MD, Professor, Chief of Cardiology and Chair of Cardiac Innovation, WVU Heart & Vascular Institute and Principal Investigator in the study, commented, “These data are extremely encouraging as they suggest a potential role of signal processed ECG in early cardiac disease detection. It is quite remarkable that MyoVista demonstrated a high diagnostic precision in detecting a state of cardiac muscle dysfunction only previously detectable using cardiac ultrasound techniques. This can eventually help in appropriate cardiac testing and reduce overall healthcare costs.”
"These positive results demonstrate that MyoVista wavECG Technology, which includes our patented signal processing methods combined with artificial intelligence, can lead to enhanced capabilities and completely new uses for electrocardiography-based (ECG) devices,” stated Mark Hilz, President and CEO of HeartSciences.
Andrew Simpson, Chairman of HeartSciences, stated, “This study of MyoVista wavelet ECG technology is a significant step towards enhancing the most commonly used low-cost, front-line tool, the 12-lead resting ECG, with new capabilities that can provide more effective risk stratification related to the early detection of heart disease.”
A total of 188 subjects referred from outpatient clinics to the Icahn School of Medicine, Mount Sinai Hospital for coronary computed tomography (CT) angiography also undertook in the same visit, comprehensive two-dimensional echocardiography (including tissue Doppler) that included assessment of LVDD. Subjects with arrhythmias, unstable angina, previous cardiac surgery, a pacemaker, chest deformity, or an inability to express well-defined mitral annular velocities due to severe mitral annular calcifications were excluded. Additional analysis was conducted related to a comparison cohort that were evaluated at WVU, Heart and Vascular Institute which further validated MyoVista wavECG healthy patient characteristics as well as age and population distribution information.
1. LV Diastolic Dysfunction and Prognosis, Dalane W. Kitzman, et al., Circulation, 2012 February 14: 125(6): 743-745. doi:10.1161.CIRCULATIONAHA.111.086843
2. Diastolic Dysfunction and Diastolic Heart Failure: Diagnostic, Prognostic and Therapeutic Aspects, Maurizio Galderisi, Cardiovascular Ultrasound, 2005, 3-9 doi:10.1186/1476-7120-3-9
HeartSciences is leading innovation in the field of electrocardiography through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence. Wavelet signal processing is currently used in many different industries as an important tool to provide insights and new valuable data related to spectral analysis of a signal. HeartSciences’ MyoVista® Wavelet ECG (wavECG™) Device is a first-to-market 12-lead resting electrocardiograph with new informatics based on wavelet signal processing. Patented informatics focus on energy related information rather than conventional voltage-based information. HeartSciences’ mission is to enable accurate, affordable screening for the early detection of heart disease.
In addition to proprietary informatics, the MyoVista wavECG Device has full 12-lead resting ECG capabilities including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The device has a 15.6-inch high-resolution touchscreen display and incorporates many features commonly associated with a tablet device requiring minimal user training with no change in ECG clinical workflow. The MyoVista wavECG Device is not currently available for commercial sale or distribution in the United States.
HeartSciences is a privately-held U.S. corporation based in Southlake, Texas.
For more information visit www.heartsciences.com.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Speech Processing Solutions Signs ORdigiNAL to Increase Channel Distribution in UK & Ireland of its Voice-to-Text Hardware, Software and Cloud Solutions26.4.2018 14:00 | Tiedote
Speech Processing Solutions, the world number one in professional dictation, is delighted to announce a new partnership with ORdigiNAL, a leading European distributor of speech recognition, dictation, document creation and telephony products. ORdigiNAL will act as specialist distributor in the UK and Ireland for Philips’ professional dictation hardware, software and cloud services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180426005787/en/ Philips Dictation (Photo: Business Wire) As part of the agreement, ORdigiNAL will supply Philips’ digital voice recorders, voice-to-text workflow software for small business and Enterprise, speech recognition solutions, and Cloud transcription services to resellers and integrators, especially those operating in the medical and legal markets. Philips’ voice technology comprehensive portfolio include digital recording hardware, speech recognition and dictation workflow software and clou
BIOCAD: Interleukin-17 Inhibitor Shows High Efficacy After One Year of Therapy in Psoriasis Patients26.4.2018 12:08 | Tiedote
In March 2018, BIOCAD analyzed results from its Phase II study in which the original Russian IL-17 inhibitor proved highly effective in long-term therapy in patients with severe psoriasis. The drug also showed great results in the treatment of ankylosing spondylitis. BCD-085 is an original monoclonal antibody drug blocking interleukin-17, a cytokine playing a key role in developing and maintaining various autoimmune and immunoinflammatory diseases. The majority of psoriasis patients have serious psychological problems due to social isolation, while patients with ankylosing spondylitis may rapidly become disabled if diagnosed late or treated inappropriately. Both diseases are a serious medical and social challenge, especially because they often affect young people of working age (22 to 35 years old). The European market of IL-17 inhibitors is over $700 million and it’s going to grow to $1 677 million within next 5 years. BIOCAD expects to occupy an essential share of this perspective ma
Ecole hôtelière de Lausanne (EHL) Wins Best Employer Ranking26.4.2018 11:17 | Tiedote
Ecole hôtelière de Lausanne (EHL) wins the title of Best Employer in French-speaking Switzerland in the category of medium-sized companies in the annual ranking of the magazine Bilan published this week. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180426005645/en/ Ecole hôtelière de Lausanne (EHL) Offering a dynamic and pleasant work environment on the campus north of Lausanne, the 464 employees of 33 nationalities benefit, among other things, from home-office opportunities, seven weeks of vacation, access to sport facilities and up to three free meals a day. Reacting to the announcement, CEO of the EHL Group, Mr Rochat said "the quality of the work environment is one of the priorities set for the EHL management. It is important for us to be able to attract and retain the best talent to continue to provide the best training to our students, and maintain our leadership position in teaching Hospitality Management. We work o
Alibaba Cloud Receives MySQL Corporate Contributor Award26.4.2018 11:00 | Tiedote
Alibaba Cloud, the cloud computing arm of Alibaba Group, has won the 2018 MySQL Community Awards: Corporate Contributor, which recognizes its contribution to the MySQL ecosystem, the world’s most popular open source database. The award, presented earlier this week at the Percona Live conference held in Santa Clara, California, is another accolade for the global cloud services provider. The award recognized Alibaba Cloud’s contributions to the open source communities and its efforts to empower developers around the world in recent years. Today, more than one hundred thousand MySQL instances are running on ApsaraDB for RDS, Alibaba Cloud’s relational database services. This is the second time Alibaba has received the coveted award from the MySQL community. In 2015, Alibaba Group became the first Asian company to be named a WebScaleSQL Contributor, alongside Facebook, Google, Twitter and LinkedIn. The award is a ‘from-the-community, by-the-community, and for-the-community’ initiative and
Ripple Grows Its Global Payments Network With Five New xVia Customers26.4.2018 11:00 | Tiedote
Ripple, the enterprise blockchain solution for global payments, is announcing that five new customers across Europe and Asia - FairFX (U.K.), RationalFX (U.K.), Exchange4Free (U.K.), UniPAY (Georgia), and MoneyMatch (Malaysia) - will use xVia to power frictionless payments over RippleNet. Requiring just one standard integration, xVia is an API solution enabling payment originators - those sending a payment on behalf of a customer, but not actually processing and paying it out - to access and reap the benefits of RippleNet. This includes faster entry into new markets, lower operational costs, increased speed and end-to-end visibility over a payment’s journey. “By tapping our global network with xVia, our customers now access new markets quicker and cost efficiently,” said Asheesh Birla, senior vice president of product at Ripple. “All of these customers run into the same problem: building bespoke connections to banks and networks all over the world. It’s expensive and time consuming. xV
Bentley Systems Acquires Plaxis, and Complementary SoilVision, to Integrate Geotechnical Engineering within Digital Workflows for Infrastructure Projects26.4.2018 09:00 | Tiedote
Bentley Systems, Incorporated, a leading global provider of comprehensive software solutions for advancing infrastructure, today announced the acquisition of Plaxis, the leading provider of geotechnical software, based in Delft, Netherlands, and the agreement to acquire soil engineering software provider SoilVision, based in Saskatchewan, Canada. The acquisitions, with Bentley’s market-leading borehole reporting and data management software gINT, serve to make Bentley a complete source for geotechnical professionals “going digital.” Finally, BIM advancements can be extended to the essential subsurface engineering of every infrastructure project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180425006935/en/ PLAXIS 3D performs three-dimensional analysis of deformation, soil-structure interaction, and stability in geotechnical engineering and rock mechanics. Projects necessarily begin with geotechnical surveys and sampling, c
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme